Evidence map›Paper›PMID 33968060›Full record

ArticleFrontiers in immunology2021

HLA-A*11:01:01:01, HLA-C*12:02:02:01-HLA-B*52:01:02:02, Age and Sex Are Associated With Severity of Japanese COVID-19 With Respiratory Failure.

Seik-Soon Khor, Yosuke Omae, Nao Nishida, Masaya Sugiyama, Noriko Kinoshita, Tetsuya Suzuki, Michiyo Suzuki, Satoshi Suzuki, Shinyu Izumi, Masayuki Hojo and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Narrative Review Explaining the Role ofInfectious disease reports · 2024
    Review
  10. Article
  11. Article
  12. Article
  13. The molecular mechanisms of CD8Frontiers in immunology · 2024
    Review
  14. Article
  15. Review
  16. Review
  17. The immunogenetics of COVID-19.Immunogenetics · 2023
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Seik-Soon KhorGenome Medical Science Project, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
Yosuke OmaeGenome Medical Science Project, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
Nao NishidaGenome Medical Sciences Project, National Center for Global Health and Medicine, Ichikawa, Japan.
Masaya SugiyamaGenome Medical Sciences Project, National Center for Global Health and Medicine, Ichikawa, Japan.
Noriko KinoshitaDisease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
Tetsuya SuzukiDisease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
Michiyo SuzukiDisease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
Satoshi SuzukiBiobank, National Center for Global Health and Medicine, Tokyo, Japan.
Shinyu IzumiDepartment of Respiratory Medicine, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
Masayuki HojoDepartment of Respiratory Medicine, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
Norio OhmagariDisease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
Masashi MizokamiGenome Medical Sciences Project, National Center for Global Health and Medicine, Ichikawa, Japan.
Katsushi TokunagaGenome Medical Science Project, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
National Center for Global Health and Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing coronavirus disease 2019 (COVID-19) was announced as an outbreak by the World Health Organization (WHO) in January 2020 and as a pandemic in March 2020. The majority of infected individuals have experienced no or only mild symptoms, ranging from fully asymptomatic cases to mild pneumonic disease. However, a minority of infected individuals develop severe respiratory symptoms. The objective of this study was to identify susceptible HLA alleles and clinical markers that can be used in risk prediction model for the early identification of severe COVID-19 among hospitalized COVID-19 patients. A total of 137 patients with mild COVID-19 (mCOVID-19) and 53 patients with severe COVID-19 (sCOVID-19) were recruited from the Center Hospital of the National Center for Global Health and Medicine (NCGM), Tokyo, Japan for the period of February-August 2020. High-resolution sequencing-based typing for eight HLA genes was performed using next-generation sequencing. In the HLA association studies, HLA-A*11:01:01:01 [P

Indexed as

Age FactorsCase-Control StudiesComorbidityCOVID-19FemaleGene FrequencyGenetic Association StudiesHaplotypesHigh-Throughput Nucleotide SequencingHLA-A11 AntigenHLA-B52 AntigenHLA-C AntigensHumansJapanMaleMiddle AgedHLA-A*11:01 antigenHLA-A11 AntigenHLA-B*52:01 antigenHLA-B52 AntigenHLA-C Antigensallelecase-control analysisCOVID-19haplotypeHLAsusceptibility genes

Identifiers

PMID33968060
PMCPMC8100314
OpenAlexW3161210266

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.